Balanitis

1. Clinical Overview

Summary

Balanitis is inflammation of the glans penis, while balanoposthitis includes concurrent inflammation of the prepuce (foreskin). It represents one of the most common urological presentations affecting 3-11% of males across the lifespan. [1] The condition is predominantly infectious (candidal or bacterial) or inflammatory (contact dermatitis, lichen sclerosus, psoriasis), with Candida albicans being the leading infective pathogen. [2] Uncircumcised status and diabetes mellitus are the strongest risk factors, with diabetes conferring a 3-4 fold increased risk of candidal balanitis. [3,4] Recurrent candidal balanitis should trigger screening for undiagnosed type 2 diabetes, as genital candidiasis may be the presenting manifestation in 10-15% of new diabetes diagnoses. [5] Management is aetiology-specific: topical antifungals for candida, antibiotics for bacterial infection, and potent topical corticosteroids for inflammatory dermatoses. Recurrent or refractory cases often require circumcision, which is curative in over 90% of cases. [6]

Key Facts

• Prevalence: 3% of boys; 11% of adult men; 12-14% of men attending GUM clinics [1]
• Most common causes: Candida albicans (30-35%), poor hygiene/irritant dermatitis (25-30%), bacterial (15-20%), dermatoses (10-15%) [2]
• Key risk factors: Uncircumcised status (OR 3.1), diabetes mellitus (OR 3.8), poor hygiene, immunosuppression [3,4]
• Red flag: Recurrent candidal balanitis → check HbA1c (10-15% have undiagnosed diabetes) [5]
• Management: Treat underlying cause; hygiene education; circumcision for recurrent disease (> 90% cure rate) [6]
• Complications: Phimosis (5-10%), urethral stricture (lichen sclerosus), SCC risk (~5% with chronic lichen sclerosus) [7,8]

Clinical Pearls

Think Diabetes First: Up to 35% of men with recurrent candidal balanitis have undiagnosed type 2 diabetes. Always check HbA1c in any man with more than one episode. [3,5] SGLT2 inhibitors can precipitate candidal balanitis even in non-diabetic patients due to glycosuria. [9]

Avoid Soap and Over-Washing: The preputial space has a physiological microbiome. Excessive hygiene with soap disrupts this balance, causing irritant contact dermatitis—the second most common cause of balanitis. Advise water-only washing or soap substitutes. [10]

Lichen Sclerosus is Not Benign: Also known as balanitis xerotica obliterans (BXO), this chronic scarring condition carries a 4-8% lifetime risk of squamous cell carcinoma. Requires potent topical corticosteroids and long-term dermatology or urology surveillance. [7,8]

Zoon's Balanitis (Plasma Cell Balanitis): Well-demarcated, orange-red, "cayenne pepper" glazed plaques on glans. Benign condition seen in elderly uncircumcised men. Histology shows dense plasma cell infiltrate. Circumcision is curative. [11]

Paraphimosis is an Emergency: Foreskin trapped in retracted position causes venous congestion and glans oedema. If not reduced promptly, can lead to arterial compromise and necrosis. Manual reduction under local anaesthesia is first-line; dorsal slit or circumcision if unsuccessful. [12]

Why This Matters Clinically

Balanitis is generally straightforward to diagnose and manage, but carries important implications:

1. Diabetes screening: A window for early detection of type 2 diabetes [5]
2. Malignancy risk: Chronic inflammatory states (especially lichen sclerosus) predispose to SCC [7,8]
3. STI marker: May indicate sexually transmitted infections (HSV, Trichomonas, syphilis) requiring partner notification [13]
4. Quality of life: Significant impact on sexual function and psychological well-being [14]
5. Phimosis and surgical burden: Recurrent disease leads to pathological phimosis requiring circumcision [6]

---

2. Epidemiology

Incidence & Prevalence

• Children: Affects 3-4% of uncircumcised boys, most commonly aged 2-5 years [1]
• Adults: Lifetime incidence 11-13% in uncircumcised men; 2-3% in circumcised men [1,15]
• GUM clinic setting: 12-14% of male attendees present with balanitis or balanoposthitis [2]
• Primary care: Estimated 1-2 consultations per 1,000 registered male patients annually [15]

Demographics

Risk Factors

Major Risk Factors (Odds Ratio > 2)

Minor Risk Factors (Odds Ratio less than 2)

Special Populations

Diabetes mellitus: Candidal balanitis occurs in 15-20% of diabetic men vs 5-8% of non-diabetic men. [3,4] HbA1c > 8% (64 mmol/mol) significantly increases risk. Recurrent candidal balanitis may be the presenting feature in 10-15% of newly diagnosed type 2 diabetes. [5]

HIV/Immunosuppression: 20-30% of HIV-positive men experience balanitis, often with atypical or severe presentations. [17] May be caused by opportunistic organisms (Candida krusei, CMV, Mycobacterium).

SGLT2 Inhibitor Users: Canagliflozin, dapagliflozin, empagliflozin cause glucosuria. Meta-analyses report genital mycotic infections in 3.7% (95% CI 2.8-4.9%) vs 0.6% placebo. [9] Risk highest in first 6 months; predominantly candidal balanitis or vulvovaginitis.

---

3. Pathophysiology

Normal Physiology of the Prepuce

The uncircumcised penis has a preputial sac between the glans and inner prepuce, which:

• Maintains physiological flora (lactobacilli, coagulase-negative staphylococci, diphtheroids)
• Secretes smegma (desquamated epithelial cells, sebum) with antimicrobial properties
• Requires balance between moisture retention and cleanliness [10]

Disruption of this balance (over-washing or under-washing) precipitates inflammation.

Aetiology and Mechanisms

1. Candidal Balanitis (30-35% of cases) [2]

Pathogen: Predominantly Candida albicans (90%); occasionally non-albicans species (C. glabrata, C. krusei)

Pathophysiology:

• Candida is a commensal yeast on skin and mucous membranes in 15-30% of healthy individuals [19]
• Opportunistic overgrowth occurs when:
  • "Glycosuria (diabetes, SGLT2 inhibitors): glucose in urine creates nutrient-rich environment for Candida in preputial sac [3,4]"
  • "Impaired immunity: diabetes impairs neutrophil chemotaxis and phagocytosis; HIV reduces CD4+ T-cell immunity [17]"
  • "Antibiotic use: disrupts bacterial flora, allowing fungal overgrowth"
  • "Moisture and warmth: poor hygiene, obesity, tight clothing"
• Candida adheres to epithelial cells via adhesins and invades superficial layers, triggering inflammatory response

Clinical presentation: Erythema, white curdy discharge, satellite lesions, intense pruritus

Diabetes link:

• Prevalence of candidal balanitis: 15-20% in diabetic men vs 5-8% in non-diabetic [3,4]
• HbA1c > 8% (64 mmol/mol) confers highest risk [5]
• Recurrent episodes (≥2 per year) strongly suggest undiagnosed diabetes (positive predictive value ~40%) [5]

Candidal vs Bacterial Differentiation:

A systematic approach to distinguishing candidal from bacterial balanitis is critical for targeted therapy:

Mixed infections occur in 5-10% of cases, particularly in immunocompromised patients or those with severe neglected hygiene. [22]

2. Bacterial Balanitis (15-20% of cases) [2]

Organisms:

• Aerobic: Streptococcus pyogenes (Group A Strep), Staphylococcus aureus, Staphylococcus haemolyticus [22]
• Anaerobic: Bacteroides, Prevotella (associated with poor hygiene)

Pathophysiology:

• Bacterial overgrowth due to poor hygiene, smegma accumulation
• Direct invasion of epithelium; release of toxins (streptococcal exotoxins)
• Often secondary infection of pre-existing dermatosis or trauma
• S. haemolyticus can cause erosive balanitis even in circumcised, healthy males [22]

Clinical presentation: Purulent discharge, intense erythema, oedema, occasionally erosions/ulceration

Rare severe forms:

• Fournier's gangrene: Necrotising fasciitis of the genitalia; polymicrobial (aerobic + anaerobic); surgical emergency [20]

3. Dermatological Balanitis (10-15% of cases)

a. Lichen Sclerosus (Balanitis Xerotica Obliterans—BXO) [7,8]

Pathophysiology:

• Autoimmune etiology: T-cell mediated inflammation targeting dermal-epidermal junction
• Leads to dermal sclerosis, epidermal atrophy, basement membrane thickening
• Genetic factors: HLA-DQ7 association
• Environmental triggers: Koebner phenomenon (trauma), chronic urine exposure

Progression:

1. Early: white plaques on glans/prepuce
2. Intermediate: scarring → phimosis
3. Advanced: meatal stenosis, urethral stricture
4. Long-term: 4-8% develop squamous cell carcinoma [7,8]

Histology: Hyperkeratosis, basal layer vacuolisation, dermal hyalinisation, band-like lymphocytic infiltrate

b. Zoon's Balanitis (Plasma Cell Balanitis) [11]

Pathophysiology:

• Unknown aetiology; hypothesis: chronic irritation (smegma, urine) triggers plasma cell infiltrate
• Almost exclusively in elderly uncircumcised men
• Benign; no malignant potential

Histology: Dense subepithelial plasma cell infiltrate, epidermal thinning, dilated capillaries

Clinical presentation: Well-demarcated, orange-red, glazed "cayenne pepper" plaques on glans

c. Psoriasis [21]

• 2-5% of men with psoriasis develop genital involvement
• Koebner phenomenon: trauma triggers new lesions
• Typically lacks scale on glans (moist environment)
• May be isolated genital psoriasis without plaques elsewhere

d. Fixed Drug Eruption

• Localized hyperpigmented patch/plaque that recurs at same site with drug re-exposure
• Common culprits: NSAIDs, antibiotics (sulfonamides, tetracyclines), paracetamol

4. Irritant and Allergic Contact Dermatitis (25-30% of cases) [10]

Irritant contact dermatitis (more common):

• Soap, shower gel, bubble bath: alkaline pH disrupts acid mantle, damages stratum corneum
• Over-washing: removes protective sebum and physiological flora [10]

Allergic contact dermatitis (Type IV hypersensitivity):

• Latex condoms: natural rubber latex proteins
• Spermicides: nonoxynol-9
• Topical medications: preservatives, fragrances

5. Sexually Transmitted Infections (5-10% of cases) [13]

6. Reactive Arthritis (Circinate Balanitis) [18]

• Part of classic triad: arthritis, urethritis, conjunctivitis
• Triggered by Chlamydia trachomatis or enteric infections (Salmonella, Shigella, Campylobacter, Yersinia)
• Presents as circinate balanitis: annular erythematous plaques with central clearing on glans
• Mechanism: autoimmune cross-reactivity to bacterial antigens

---

4. Clinical Presentation

Symptom Spectrum

Common Symptoms

• Penile discomfort: Soreness, tenderness, burning sensation (85-95% of cases) [2]
• Pruritus: Itching, especially with candidal balanitis (70-80%)
• Erythema: Redness of glans and/or prepuce (90-100%)
• Discharge: White curdy (candida), purulent (bacterial), minimal (dermatoses) (50-70%)
• Dysuria: Painful urination, especially at meatus (30-40%)
• Difficulty retracting foreskin: Painful retraction or inability to retract due to swelling/phimosis (25-35%)

Less Common Symptoms

• Bleeding: From friable inflamed tissue or erosions
• Malodour: Bacterial overgrowth, poor hygiene
• Sexual dysfunction: Pain with erection or intercourse, psychological distress [14]

Signs by Aetiology

Red Flags — Urgent Assessment Required

[!CAUTION] Immediate Referral/Emergency Assessment

1. Fournier's gangrene: Rapidly spreading erythema, ecchymosis, crepitus, systemic sepsis (fever, tachycardia, hypotension). Requires emergency surgical debridement and broad-spectrum antibiotics. Mortality 20-40%. [20]

2. Paraphimosis: Foreskin trapped in retracted position behind glans; venous congestion → arterial compromise → necrosis within hours. Requires urgent manual reduction or dorsal slit. [12]

3. Suspected penile malignancy: Non-healing ulcer > 4 weeks, indurated mass, bleeding, painless lesion. Chronic lichen sclerosus is a premalignant condition (4-8% SCC risk). [7,8]

[!WARNING] Specialist Referral (Urology/Dermatology/GUM)

1. Recurrent candidal balanitis (≥2 episodes): Screen for diabetes (HbA1c, fasting glucose). If diabetes excluded, consider immunosuppression (HIV test), chronic low-grade infection, or non-adherence to treatment. [5]

2. Suspected lichen sclerosus: Requires biopsy confirmation, potent topical corticosteroids, and long-term surveillance for malignancy. [7,8]

3. Suspected STI: Perform full STI screen, partner notification, contact tracing. [13]

4. Atypical presentation: Unusual morphology, lack of response to standard treatment, extensive disease.

5. Phimosis: If severe or symptomatic, may require circumcision.

---

5. Clinical Examination

Structured Approach

1. History Taking

Presenting complaint:

• Duration of symptoms
• Character: itch, pain, discharge (colour, consistency)
• Provoking/relieving factors
• Previous episodes (recurrent?)
• Treatment already tried (over-the-counter, prescribed)

Systematic enquiry for aetiology:

• Candidal: Recent antibiotics? Sweet-smelling urine? Thirst/polyuria? White discharge?
• Bacterial: Rapid onset? Purulent discharge? Malodor? Recent trauma?
• Dermatological: White patches (lichen sclerosus)? Psoriasis elsewhere? New products (contact)?
• STI: New sexual partner? Painful blisters (HSV)? Painless ulcer (syphilis)? Joint pain (reactive arthritis)?

Risk factor assessment:

• Diabetes: Known diabetes? HbA1c control? New symptoms (polyuria, polydipsia, weight loss)?
• Sexual history: New partners, condom use, partner symptoms, STI risk
• Hygiene practices: Washing frequency, soap use, retractability of foreskin
• Medications: Antibiotics (recent), SGLT2 inhibitors, immunosuppressants
• Dermatological history: Psoriasis, eczema, lichen sclerosus elsewhere
• Systemic symptoms: Fever, malaise, joint pain (reactive arthritis)

Circumcision status: Circumcised in infancy/adulthood, or uncircumcised?

Viva-style focused questions:

Examiner: "A 45-year-old man presents with recurrent balanitis. What specific questions would you ask?"

Model answer: "I would take a targeted history focusing on:

1. Diabetes screening questions:

   • Any known diabetes? Family history?
   • Symptoms of hyperglycemia: polyuria, polydipsia, weight loss, blurred vision?
   • If known diabetic: Current HbA1c? Medications (specifically SGLT2 inhibitors)?

2. Pattern of recurrence:

   • How many episodes in past year?
   • Any trigger factors identified (sexual activity, hygiene changes, new medications)?
   • Response to previous treatments?

3. Current episode characteristics:

   • Discharge: White and curdy (candida) vs purulent (bacterial)?
   • Satellite lesions (candida)?
   • Intense pruritus (candida) vs pain (bacterial)?
   • Odor (bacterial, especially anaerobic)?

4. Risk stratification:

   • Immunosuppression: HIV risk factors, chemotherapy, chronic steroids?
   • Sexual history: STI risk, new partners, partner symptoms?
   • Dermatological: White scarring patches (lichen sclerosus)? Psoriasis?

5. Red flags:

   • Rapidly spreading redness with systemic features (Fournier's)?
   • Foreskin stuck retracted (paraphimosis)?
   • Non-healing ulcer > 4 weeks (malignancy)?"

2. Physical Examination

Inspection (patient standing, then supine):

• General appearance: Obesity, acanthosis nigricans (diabetes marker)
• Foreskin: Retractable? If not, degree of phimosis
• Glans penis:
  • Erythema (extent, severity)
  • "Discharge (colour, consistency): white curdy (candida), purulent (bacterial), none"
  • "Ulceration/erosions: size, depth, base (clean vs necrotic), edges (well-defined vs irregular)"
  • "White plaques/patches: candida vs lichen sclerosus (atrophic, ivory-white)"
  • "Glazed appearance: Zoon's balanitis"
  • "Satellite lesions: candida"
• Coronal sulcus: Smegma accumulation?
• Urethral meatus: Stenosis (lichen sclerosus), discharge (urethritis)
• Penile shaft and scrotum: Extension of inflammation, scrotal involvement (candida), ecchymosis/crepitus (Fournier's)

Palpation:

• Inguinal lymph nodes: Size, tenderness, consistency
  • "Tender, enlarged: infection (bacterial, HSV)"
  • "Non-tender, rubbery: syphilis, malignancy"
• Penile shaft: Induration, plaques (Peyronie's disease, sclerosing lymphangitis)

Associated examination:

• Skin: Psoriatic plaques (elbows, knees, scalp), eczema
• Joints: Arthritis (reactive arthritis)
• Eyes: Conjunctivitis (reactive arthritis)

3. Retraction of Foreskin

If uncircumcised:

• Ask patient to retract foreskin himself
• If unable, assess for phimosis: physiological (young boys), pathological (scarring from lichen sclerosus or recurrent balanitis)
• Document if paraphimosis present (stuck in retracted position)

Viva-style clinical examination scenario:

Examiner: "You are asked to examine this patient's genital area who presents with balanitis. Talk me through your examination."

Model answer: "I would perform a focused genital examination with chaperone present:

Consent and positioning:

• Explain procedure, ensure privacy, obtain verbal consent
• Patient standing initially, then supine if detailed inspection needed

General inspection:

• Obesity, acanthosis nigricans (insulin resistance marker suggesting diabetes)
• Skin elsewhere: Psoriatic plaques on elbows/knees/scalp? Eczema?

Local inspection of penis (WITH and WITHOUT foreskin retracted):

Non-retracted state:

• Foreskin appearance: Normal? Oedematous? Scarred? White plaques (lichen sclerosus)?
• Any discharge visible at meatus?

Retracted state (patient retracts or I gently retract if able):

• Glans:

  • "Erythema: Extent (focal vs diffuse)? Severity (mild pink vs angry red)?"
  • "Discharge: White curdy (candida) vs purulent yellow-green (bacterial) vs none?"
  • "Ulceration: Size, depth, edges, base?"
  • "White patches: Atrophic ivory-white (lichen sclerosus) vs thick plaques (candida)?"
  • Glazed orange-red plaque (Zoon's balanitis)?

• Coronal sulcus: Smegma? Satellite lesions (small papules/pustules around main area—candidal)?

• Prepuce inner surface: Mirror findings on glans? White plaques?

• Urethral meatus: Stenosis (lichen sclerosus)? Discharge?

Retractability assessment:

• Can foreskin be fully retracted to expose entire glans and coronal sulcus?
• If not: Degree of phimosis (mild vs severe)?
• Paraphimosis check: Can foreskin be returned to normal position?

Penile shaft and scrotum:

• Extension of inflammation to shaft or scrotum (suggests candidal)?
• Ecchymosis, crepitus (Fournier's gangrene—EMERGENCY)?
• Penile shaft plaques or induration (Peyronie's, sclerosing lymphangitis)?

Inguinal lymph nodes (bilateral):

• Size, tenderness, consistency:
  • "Tender, enlarged, mobile: Infection (bacterial, HSV)"
  • "Non-tender, rubbery, fixed: Syphilis, malignancy"

Systemic examination (if indicated):

• Joints: Swelling, effusion (reactive arthritis)
• Eyes: Conjunctivitis (reactive arthritis)
• Skin: Full body examination for psoriasis, lichen sclerosus elsewhere

Summary to examiner: 'Based on my examination, this patient has [describe findings]. The likely diagnosis is [candidal/bacterial/lichen sclerosus/etc.] balanitis. I would proceed with [investigations] and [management plan].'"

---

14. Viva/OSCE Scenarios

Scenario 1: Recurrent Candidal Balanitis and Diabetes

Examiner: "A 52-year-old man presents with his third episode of balanitis in 6 months. On examination, you note white curdy discharge and satellite lesions. How would you manage this patient?"

Model answer:

"This is recurrent candidal balanitis, and the key issue is investigating the underlying cause.

Immediate management:

1. Confirm diagnosis: Swab for candida culture and sensitivity
2. Treat current episode:
   • Topical clotrimazole 1% cream BD for 14 days
   • Consider oral fluconazole 150mg single dose for rapid symptom relief
3. Hygiene education: Water-only washing, thorough drying, retract foreskin to clean

Critical investigation (MANDATORY in recurrent balanitis):

• HbA1c or fasting glucose: 10-15% of patients with recurrent candidal balanitis have undiagnosed type 2 diabetes
• Positive predictive value ~40% for diabetes

If HbA1c ≥48 mmol/mol (≥6.5%) → Diabetes diagnosed:

• Refer to primary care or endocrinology for diabetes management
• Target HbA1c less than 53 mmol/mol (7%) → reduces recurrence by ~60%
• Review medications: If on SGLT2 inhibitor, consider switching to alternative (DPP-4 inhibitor, GLP-1 agonist)

If HbA1c normal (less than 42 mmol/mol):

• Investigate other causes:
  • HIV test (if risk factors or unexplained immunosuppression)
  • Review adherence to hygiene and treatment
  • Consider partner treatment (vulvovaginal candidiasis)

Definitive management for recurrent disease:

• If ≥3 episodes despite optimal diabetes control and hygiene:
  • "Circumcision: > 90% cure rate, recommended"

Follow-up:

• Review at 2 weeks for treatment response
• If diabetes diagnosed: HbA1c at 3 months, then 6-monthly
• Patient education: Link between glucose control and infection risk"

---

Scenario 2: Lichen Sclerosus Management

Examiner: "A 60-year-old man presents with white plaques on the glans and prepuce for 6 months. You suspect lichen sclerosus. How would you manage this?"

Model answer:

"Lichen sclerosus is a chronic inflammatory condition with malignant potential, requiring long-term management and surveillance.

Confirmation of diagnosis:

• Clinical diagnosis often sufficient (ivory-white atrophic plaques)
• Biopsy if:
  • Atypical features (ulceration, induration, pigmented areas)
  • Confirm diagnosis before long-term topical steroid therapy
  • Suspicion of malignancy

Medical management (Evidence-based protocol):

Phase 1: Induction (12 weeks):

• Week 1-4: Clobetasol propionate 0.05% ointment OD
• Week 5-8: Reduce to alternate days
• Week 9-12: Reduce to twice weekly

Phase 2: Maintenance (long-term):

• Clobetasol propionate 0.05% ointment twice weekly indefinitely
• Emollient use after urination

Response assessment at 12 weeks:

• Good response (70-80%): Reduction in plaques, improved elasticity
• Partial response (10-15%): Some improvement but residual phimosis
• No response (10-15%): Consider circumcision or biopsy for SCC

Surgical management indications:

• Failure of medical therapy after 12 weeks
• Progressive phimosis
• Meatal stenosis (may require meatotomy)
• Patient preference

Long-term surveillance (CRITICAL):

• SCC risk: 4-8% lifetime risk
• Follow-up: 6-12 monthly review by urology or dermatology
• Biopsy threshold: Low—any new induration, ulceration, non-healing area
• Patient education: Explain chronic nature, malignancy risk, importance of adherence and follow-up

Red flags for malignancy:

• Non-healing ulcer > 4 weeks
• New mass or induration
• Change in appearance of existing plaques
• Bleeding → Urgent biopsy and urology referral"

---

Scenario 3: Paraphimosis Emergency

Examiner: "A 35-year-old man presents to A&E with a swollen, painful penis. The foreskin is stuck in the retracted position behind the glans. What is your immediate management?"

Model answer:

"This is paraphimosis—a urological emergency requiring urgent reduction to prevent arterial compromise and necrosis.

Pathophysiology:

• Foreskin trapped in retracted position
• Venous congestion → glans oedema → further entrapment
• If not reduced: Arterial compromise → tissue necrosis within hours

Immediate management:

Step 1: Analgesia and preparation:

• IV or oral analgesia (morphine 10mg IV or paracetamol 1g + ibuprofen 400mg PO)
• Consider penile ring block (1% lidocaine without adrenaline, dorsal penile nerve block)
• Ice packs to reduce oedema (5-10 minutes)

Step 2: Manual reduction (first-line, 90% successful):

• Technique:
  1. Apply firm compression to glans for 3-5 minutes → reduces oedema
  2. Grasp glans with index and middle fingers inside constricting band
  3. Use thumbs to push glans through constricting band
  4. Simultaneously pull foreskin forward over glans
• If successful: Observe for 30 minutes, ensure no recurrence, discharge with urology follow-up

Step 3: If manual reduction fails:

• Puncture technique (hyaluronidase injection or multiple puncture technique with 23G needle to release oedema fluid)
• Dorsal slit under local anaesthesia: Emergency surgical release of constricting band

Step 4: If still unsuccessful or severe tissue compromise:

• Emergency circumcision under general anaesthesia

Definitive management:

• Once acute episode resolved:
  • Urology outpatient review
  • Elective circumcision recommended to prevent recurrence

Prevention counseling:

• Always return foreskin to normal position after cleaning or catheterization
• If phimosis present: Address underlying cause (treat balanitis, consider circumcision)"

---

6. Investigations

Clinical Diagnosis

Most cases of balanitis are diagnosed clinically based on history and examination. [2] Investigations are targeted to:

1. Confirm aetiology (swab for candida/bacteria)
2. Identify underlying disease (diabetes, HIV)
3. Exclude STI
4. Rule out malignancy (biopsy)

First-Line Investigations

Further Investigations (Specialist Setting)

Histopathology (Biopsy) Findings

---

7. Management

Management Principles

1. Identify and treat underlying cause: Aetiology-specific therapy
2. Screen for systemic disease: Diabetes (candidal balanitis), HIV (recurrent infections), STI
3. Hygiene education: Water-only washing; avoid soap; dry glans carefully
4. Treat sexual partners if STI identified
5. Consider circumcision for recurrent or refractory disease (> 90% cure rate) [6]

Management Algorithm

                        BALANITIS
                            ↓
    ┌───────────────────────────────────────────────┐
    │  1. History and Examination                   │
    │     - Identify likely aetiology               │
    │     - Risk factors (diabetes, STI, hygiene)   │
    └───────────────────────────────────────────────┘
                            ↓
    ┌───────────────────────────────────────────────┐
    │  2. Investigations                            │
    │     - Swab (candida/bacterial culture)        │
    │     - HbA1c (if candidal)                     │
    │     - STI screen (if risk factors)            │
    │     - Biopsy (if atypical, chronic)           │
    └───────────────────────────────────────────────┘
                            ↓
    ┌───────────────────────────────────────────────┐
    │  3. Aetiology-Specific Treatment              │
    ├───────────────────────────────────────────────┤
    │  CANDIDAL → Topical antifungal ± oral         │
    │  BACTERIAL → Oral antibiotics                 │
    │  LICHEN SCLEROSUS → Potent topical steroid    │
    │  ZOON'S → Topical steroid or circumcision     │
    │  CONTACT DERMATITIS → Remove irritant, mild   │
    │                        topical steroid        │
    │  STI → STI-specific therapy + partner         │
    │        notification                           │
    └───────────────────────────────────────────────┘
                            ↓
    ┌───────────────────────────────────────────────┐
    │  4. General Measures                          │
    │     - Hygiene education (water only)          │
    │     - Dry glans thoroughly                    │
    │     - Retract foreskin to clean (if able)     │
    │     - Treat underlying diabetes if present    │
    └───────────────────────────────────────────────┘
                            ↓
    ┌───────────────────────────────────────────────┐
    │  5. Follow-Up and Recurrent Disease           │
    ├───────────────────────────────────────────────┤
    │  - Review at 2 weeks (clinical improvement?)  │
    │  - If recurrent (≥2 episodes):                │
    │    • Exclude diabetes (HbA1c)                 │
    │    • Exclude HIV (if risk factors)            │
    │    • Consider circumcision (curative > 90%)    │
    └───────────────────────────────────────────────┘

Aetiology-Specific Treatment

1. Candidal Balanitis [2,19]

First-line: Topical antifungal for 2 weeks

• Clotrimazole 1% cream BD for 14 days (most common first-line) [19]
• Miconazole 2% cream BD for 14 days
• Econazole 1% cream BD for 14 days

Adjunctive oral therapy (if extensive, recurrent, or immunosuppressed):

• Fluconazole 150mg PO single dose (can repeat at day 3 if severe) [19]
• Itraconazole 200mg PO OD for 3 days (alternative)

Management of underlying diabetes:

• Optimize glycemic control (target HbA1c less than 53 mmol/mol or 7%)
• Reduces recurrence risk by ~60% [5]

Comprehensive Diabetes Management Protocol for Recurrent Candidal Balanitis:

Diabetes mellitus is the single most important modifiable risk factor for recurrent candidal balanitis. [3,4,5] A structured approach to diabetes screening, optimization, and monitoring is essential.

Step 1: Diabetes Screening (all patients with candidal balanitis)

First episode of candidal balanitis:

• HbA1c or fasting glucose (consider HbA1c preferred for convenience)
• If HbA1c 42-47 mmol/mol (6.0-6.4%): Pre-diabetes → lifestyle advice, repeat in 6 months
• If HbA1c ≥48 mmol/mol (≥6.5%): Diabetes → refer to primary care or endocrinology

Recurrent candidal balanitis (≥2 episodes):

• Mandatory HbA1c testing: 10-15% will have undiagnosed type 2 diabetes [5]
• Positive predictive value of recurrent candidal balanitis for diabetes: ~40%
• If diabetes already known: Review current control and medications

Step 2: Glycemic Target Setting

Step 3: Diabetes Medication Review

SGLT2 Inhibitors and Balanitis [9]:

• SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) induce glucosuria independent of blood glucose
• Genital mycotic infection incidence: 3.7% (95% CI 2.8-4.9%) vs 0.6% placebo [9]
• Risk highest in first 6 months of therapy
• If patient on SGLT2 inhibitor with recurrent balanitis: Consider alternative (DPP-4 inhibitor, GLP-1 agonist)

Alternative diabetes medications preferred in recurrent balanitis:

• Metformin (first-line; no increased infection risk)
• DPP-4 inhibitors (sitagliptin, linagliptin): No glucosuria
• GLP-1 agonists (liraglutide, semaglutide): No glucosuria; weight loss benefit
• Insulin (if required): Optimize to avoid hyperglycemia

Step 4: Monitoring and Follow-Up

Initial phase (first 3 months):

• HbA1c at 3 months post-diagnosis or post-optimization
• Monthly review of balanitis symptoms (patient diary)
• Hygiene and antifungal adherence check

Maintenance phase (if diabetes controlled):

• HbA1c every 6 months
• Annual review for complications (neuropathy, nephropathy, retinopathy)
• Patient education: Link between glucose control and infection risk

If recurrence despite HbA1c less than 53 mmol/mol:

• Investigate other causes: HIV, immunosuppression, poor hygiene adherence, partner re-infection
• Consider circumcision (curative in > 90%) [6,24]

Partner treatment:

• Screen female partner for vaginal candidiasis (treat if symptomatic)
• Not routinely treated if asymptomatic

Recurrent candidal balanitis (≥2 episodes per year):

• Investigate: HbA1c, fasting glucose, HIV test (if risk factors)
• Prophylaxis: Fluconazole 150mg PO once weekly for 6 months (consider if recurrent and diabetes controlled)
• Definitive: Circumcision (curative in > 90%) [6]

2. Bacterial Balanitis [2]

First-line oral antibiotics (7-10 days):

• Co-amoxiclav 625mg PO TDS for 7 days (covers Strep, Staph, anaerobes)
• Flucloxacillin 500mg PO QDS for 7 days (if penicillin-allergic: clarithromycin 500mg BD)
• Metronidazole 400mg PO TDS for 7 days (if anaerobic suspected—malodorous discharge, poor hygiene)

Severe/systemic infection:

• IV antibiotics (co-amoxiclav 1.2g TDS or ceftriaxone + metronidazole)
• Fournier's gangrene: Surgical emergency—broad-spectrum IV antibiotics + urgent surgical debridement [20]

3. Lichen Sclerosus (Balanitis Xerotica Obliterans—BXO) [7,8]

First-line: Potent topical corticosteroid

• Clobetasol propionate 0.05% ointment OD for 4 weeks, then alternate days for 4 weeks, then twice weekly maintenance [7,8,23]
• Mometasone furoate 0.1% ointment OD (alternative if clobetasol not tolerated)

Evidence-based protocol for lichen sclerosus [23]:

Phase 1: Induction (12 weeks)

• Week 1-4: Clobetasol propionate 0.05% ointment applied to affected area once daily
• Week 5-8: Reduce to alternate days (3-4 times per week)
• Week 9-12: Reduce to twice weekly

Phase 2: Maintenance (long-term)

• Clobetasol propionate 0.05% ointment twice weekly indefinitely
• Review every 3-6 months for:
  • Clinical response (reduction in white plaques, improvement in elasticity)
  • Side effects (skin atrophy—rare on genital skin due to moisture)
  • Malignant transformation (new induration, ulceration, non-healing areas)

Adjunctive measures:

• Emollient use (emulsifying ointment or aqueous cream) after urination to reduce irritation
• Avoid irritants (soap, perfumed products)
• Patient education: Explain chronic nature, importance of adherence, SCC risk (4-8%)

Response assessment:

• Good response (70-80% of patients): Reduction in white plaques, improved foreskin retractability, reduced symptoms [7,23]
• Partial response (10-15%): Some improvement but residual phimosis or meatal stenosis
• No response (10-15%): Progressive disease despite therapy → consider circumcision or biopsy to exclude SCC

Goals:

• Halt progression
• Prevent phimosis and urethral stricture
• Reduce SCC risk

Long-term management:

• Urology or dermatology follow-up: 6-12 monthly review
• Biopsy any suspicious areas (induration, ulceration, change in appearance)
• Circumcision: Indicated if medical therapy fails, phimosis develops, or meatal stenosis occurs [6,7,23]
  • Curative in early disease (glans/prepuce only)
  • May require meatotomy or urethroplasty if urethral involvement

Surveillance for malignancy:

• Lifetime SCC risk 4-8% [7,8,23]
• Annual examination; biopsy suspicious lesions
• Histological subtypes associated with neoplasia include lymphocytic-depleted variant [23]

4. Zoon's Balanitis (Plasma Cell Balanitis) [11]

First-line: Potent topical corticosteroid

• Clobetasol propionate 0.05% ointment OD for 4-8 weeks

Alternatives:

• Topical tacrolimus 0.1% ointment BD (calcineurin inhibitor; steroid-sparing)

Definitive treatment:

• Circumcision: Curative in > 95% of cases [11]
• Benign condition; no malignant potential

5. Psoriatic Balanitis [21]

First-line: Mild-to-moderate topical corticosteroid

• Hydrocortisone 1% cream BD for 2-4 weeks (genital skin is thin; avoid potent steroids)
• Betamethasone valerate 0.1% ointment OD (if hydrocortisone insufficient)

Alternatives:

• Topical tacrolimus 0.1% ointment BD (steroid-sparing; good for maintenance)
• Topical vitamin D analogues (calcipotriol): avoid on genital skin (irritant)

Systemic therapy (if widespread psoriasis):

• Coordinate with dermatology (methotrexate, biologics)

6. Contact Dermatitis (Irritant or Allergic) [10]

Irritant contact dermatitis (soap, over-washing):

• Remove irritant: Stop soap; wash with water only or emollient (e.g., emulsifying ointment)
• Mild topical corticosteroid: Hydrocortisone 1% cream BD for 1-2 weeks

Allergic contact dermatitis (latex, spermicides):

• Identify and avoid allergen: Switch to non-latex condoms (polyurethane, polyisoprene), avoid spermicides
• Topical corticosteroid: Hydrocortisone 1% cream BD for 1-2 weeks
• Patch testing if allergen unclear

7. Sexually Transmitted Infections [13]

Partner notification: Essential for all STIs; coordinate with GUM clinic [13]

8. Fixed Drug Eruption

• Identify and avoid causative drug: Detailed medication history (including over-the-counter, supplements)
• Topical corticosteroid: Mild-to-moderate potency for 1-2 weeks

General Measures (All Patients)

Hygiene Education [10]

Key advice:

1. Wash with water only (no soap, shower gel, or bubble bath)
2. Soap substitutes if needed: emulsifying ointment, aqueous cream
3. Retract foreskin gently (if retractable) to clean glans and coronal sulcus
4. Dry thoroughly after washing (pat dry with soft towel)
5. Avoid over-washing: Once daily is sufficient
6. Loose-fitting underwear: Cotton, breathable fabrics

Common misconception: "More washing = better hygiene"

• Over-washing with soap causes irritant dermatitis and disrupts protective microbiome [10]

Treat Underlying Conditions

• Diabetes: Optimize glycemic control (target HbA1c less than 53 mmol/mol) [5]
• Obesity: Weight loss improves genital hygiene access and reduces moisture
• Immunosuppression: Optimize HIV viral load, review immunosuppressive medications

Surgical Management

Indications for Circumcision [6,24]

Evidence-based indications with cure rates from systematic reviews and cohort studies:

Patient selection for circumcision:

Absolute indications (should be offered):

1. Pathological phimosis preventing retraction
2. Recurrent balanitis (≥2-3 episodes) despite:
   • Optimal medical therapy
   • Diabetes control (HbA1c less than 53 mmol/mol)
   • Hygiene education compliance
3. Lichen sclerosus with:
   • Failure of 12 weeks topical clobetasol therapy
   • Progressive phimosis or meatal stenosis
   • Patient preference after discussion of risks/benefits
4. Zoon's balanitis (curative)

Relative indications (consider on case-by-case basis):

1. Single episode of severe balanitis with complications (paraphimosis, urinary retention)
2. Patient preference in setting of recurrent mild balanitis
3. Diabetes with poor glycemic control and recurrent candidal balanitis (circumcision + diabetes optimization)
4. Occupational factors (limited access to hygiene facilities)

Contraindications:

• Active acute infection (defer until treated)
• Suspected penile malignancy (requires oncological assessment first)
• Bleeding diathesis (requires hematology input)
• Patient preference against procedure after informed discussion

Pre-operative counseling:

• Success rates: > 90% cure for recurrent balanitis [6,24]
• Complications (5-10%): Bleeding, infection, meatal stenosis (2-3%), excessive skin removal, poor cosmesis, reduced sexual sensation (controversial, ~10-15% report change)
• Alternatives: Long-term topical therapy, preputioplasty (dorsal slit)
• Recovery: 2-3 weeks; avoid sexual activity for 4-6 weeks
• Irreversibility: Cannot restore foreskin after circumcision

Circumcision Procedure

• Day case under general or local anaesthesia
• Technique: Removal of prepuce; mucosa sutured to skin edge
• Complications (5-10%): Bleeding, infection, meatal stenosis, excessive skin removal, poor cosmesis

Alternatives to Circumcision

• Preputioplasty: Dorsal slit or widening of preputial opening; preserves foreskin
  • Indicated in phimosis with minimal scarring
  • Higher recurrence rate than circumcision

---

8. Complications

Acute Complications

Chronic Complications

Malignancy Risk

Lichen sclerosus and SCC [7,8]:

• Cumulative lifetime risk: 4-8%
• Mechanism: Chronic inflammation → TP53 mutations → dysplasia (penile intraepithelial neoplasia, PeIN) → invasive SCC
• Surveillance: Annual examination by dermatologist or urologist; low threshold for biopsy
• Prevention: Potent topical corticosteroids may reduce SCC risk (not proven in RCTs)

HPV and penile cancer:

• HPV (especially type 16) is implicated in ~50% of penile SCCs
• Not a direct complication of balanitis, but HPV-related balanitis lesions (subclinical infection) may progress

---

9. Prognosis & Outcomes

Outcomes by Aetiology

Factors Affecting Prognosis

Positive Prognostic Factors

• Diagnosis and treatment within first week: Faster resolution, lower complication risk
• Good glycemic control (HbA1c less than 53 mmol/mol): Reduces candidal recurrence by ~60% [5]
• Adherence to hygiene advice: Water-only washing reduces irritant dermatitis recurrence [10]
• Circumcision for recurrent disease: > 90% cure rate [6]

Negative Prognostic Factors

• Uncontrolled diabetes (HbA1c > 8%): 60-70% recurrence rate for candidal balanitis [5]
• Immunosuppression (HIV, chemotherapy, steroids): Recurrent, severe, or atypical infections [17]
• Poor adherence: Non-compliance with treatment or hygiene measures
• Lichen sclerosus: Progressive disease; 4-8% SCC risk [7,8]
• Delayed diagnosis: Increased risk of phimosis, stricture, chronic pain

Quality of Life Impact [14]

• Sexual dysfunction: 20-30% report reduced sexual activity due to pain, embarrassment, or scarring
• Psychological distress: Anxiety, depression, relationship strain
• Urinary symptoms: Dysuria, poor stream (if meatal stenosis/stricture)
• Improvement with treatment: Most patients report significant QoL improvement within 2-4 weeks of appropriate therapy

Natural History if Untreated

• Candidal/bacterial: May resolve spontaneously in mild cases; often progresses to chronic inflammation
• Lichen sclerosus: Progressive scarring → phimosis → meatal stenosis → urethral stricture [7,8]
• Zoon's balanitis: Benign; persists indefinitely; no spontaneous resolution [11]
• Contact dermatitis: Persists if exposure continues; resolves if irritant/allergen removed [10]

---

10. Prevention

Primary Prevention

General Population

1. Hygiene education: Water-only washing; avoid soap on glans [10]
2. Avoid over-washing: Once daily sufficient; over-washing disrupts physiological microbiome
3. Safe sexual practices: Condoms reduce STI-related balanitis [13]
4. Avoid allergens: Non-latex condoms if latex allergy; avoid spermicides if sensitive

Neonatal Circumcision

• Highly effective: Reduces balanitis incidence by ~60-70% [15]
• Controversial: Cultural, religious, and ethical considerations
• Not routinely recommended in UK/Australia for prophylaxis alone (unlike USA where more common)

Secondary Prevention (Preventing Recurrence)

In Patients with Diabetes [5]

• Optimize glycemic control: Target HbA1c less than 53 mmol/mol (7%)
  • Reduces candidal balanitis recurrence by ~60%
• Regular monitoring: HbA1c every 3-6 months
• Patient education: Link between glucose control and infection risk

In Patients with Recurrent Balanitis [6]

• Hygiene counselling: Water-only washing, dry thoroughly
• Identify and treat underlying causes: Diabetes, HIV, poor hygiene
• Prophylactic antifungals: Fluconazole 150mg PO once weekly for 6 months (if recurrent candida and circumcision declined)
• Circumcision: Definitive; > 90% cure rate

In Patients with Lichen Sclerosus [7,8]

• Long-term topical corticosteroids: Clobetasol 0.05% twice weekly maintenance
• Annual surveillance: Dermatology or urology review; biopsy suspicious lesions
• Sun protection: Avoid UV exposure (theoretical risk factor)

Tertiary Prevention (Preventing Complications)

• Early treatment: Reduces risk of phimosis, stricture, SCC
• Avoid delay in diagnosis: Educate patients to seek help early
• Regular follow-up: For lichen sclerosus (malignancy surveillance), HIV (immune monitoring)

---

11. Patient/Layperson Explanation

What is Balanitis?

Balanitis is inflammation (redness and swelling) of the head of the penis (glans). If the foreskin is also inflamed, it's called balanoposthitis. It's common—about 1 in 10 men will get it at some point in their lives.

What Causes It?

The most common causes are:

1. Thrush (yeast infection): Caused by a fungus called Candida. This is especially common if you have diabetes, as sugar in your urine helps the fungus grow.

2. Bacterial infection: Less common. Caused by bacteria like Streptococcus or Staphylococcus.

3. Irritation from soap: Washing with soap or shower gel can irritate the sensitive skin of the penis. Water-only washing is better.

4. Skin conditions: Such as lichen sclerosus (white patches that scar), psoriasis, or eczema.

5. Sexually transmitted infections: Such as herpes or syphilis (less common).

6. Allergy: To latex condoms, spermicides, or other products.

What Are the Symptoms?

• Redness and swelling of the penis head
• Itching or soreness
• White discharge (if thrush)
• Pain when peeing
• Difficulty pulling back the foreskin

How is it Diagnosed?

Your doctor will examine your penis and ask about your symptoms. They may:

• Take a swab to check for thrush or bacteria
• Test your blood sugar (diabetes test) if you have thrush
• Check for sexually transmitted infections if you're sexually active

How is it Treated?

Treatment depends on the cause:

1. Thrush: Antifungal cream (e.g., clotrimazole) twice daily for 2 weeks. Sometimes a tablet (fluconazole) is also given.

2. Bacterial infection: Antibiotic tablets for 7 days.

3. Lichen sclerosus (white patches): Strong steroid cream for several weeks. You'll need regular check-ups, as this condition can increase cancer risk slightly.

4. Irritation from soap: Stop using soap. Wash with water only. A mild steroid cream may help.

5. Sexually transmitted infection: Specific antibiotics or antivirals. Your partner will also need treatment.

General advice for everyone:

• Wash with water only (no soap)
• Dry the area carefully
• If you have diabetes, keep your blood sugar under control

When Should I See a Doctor Urgently?

See a doctor immediately if you have:

• Severe pain and rapidly spreading redness (this could be a serious infection called Fournier's gangrene)
• Your foreskin is stuck in a pulled-back position and won't go back (paraphimosis—a medical emergency)
• A sore that doesn't heal after 4 weeks (could be cancer)

See a doctor soon if:

• Symptoms don't improve after 1-2 weeks of treatment
• You keep getting balanitis (you may need a diabetes test or circumcision)

Can Balanitis Be Prevented?

Yes! Here's how:

1. Good hygiene:

   • Wash gently with water only (no soap)
   • Pull back your foreskin gently to clean underneath (if you have a foreskin)
   • Dry thoroughly

2. Avoid irritants:

   • Don't use soap, shower gel, or bubble bath on your penis
   • If you're allergic to latex, use non-latex condoms

3. Manage diabetes:

   • If you have diabetes, keep your blood sugar well controlled

4. Circumcision:

   • If you keep getting balanitis despite treatment, circumcision (surgical removal of the foreskin) can cure it in over 90% of cases

Will it Come Back?

• If the cause is treated: Most cases don't come back.
• If you have diabetes and it's not well controlled, thrush can keep coming back.
• If you have a skin condition like lichen sclerosus, you'll need ongoing treatment and check-ups.
• Circumcision prevents recurrence in most cases.

Is Balanitis Serious?

Most of the time, no. It's uncomfortable but responds well to treatment.

However:

• Recurrent thrush may be a sign of undiagnosed diabetes—get your blood sugar checked.
• A condition called lichen sclerosus (white scarring patches) has a small risk of turning into cancer over many years, so you'll need regular check-ups.
• If you have severe pain and spreading redness, see a doctor immediately—this could be a serious infection.

---

12. Evidence & Guidelines

Key Guidelines

1. Clinical Effectiveness Group, BASHH (British Association for Sexual Health and HIV). UK National Guideline on the Management of Balanitis, 2018.

   • Evidence-based recommendations for diagnosis and management
   • Available at: https://www.bashh.org

2. European Association of Urology (EAU). Guidelines on Penile Diseases, 2023.

   • Comprehensive guideline covering balanitis, phimosis, lichen sclerosus, and penile cancer
   • Available at: https://uroweb.org

3. British Association of Dermatologists (BAD). Guidelines for the Management of Lichen Sclerosus, 2018.

   • Detailed guidance on lichen sclerosus diagnosis, treatment, and surveillance
   • Available at: https://www.bad.org.uk

4. American Academy of Dermatology (AAD). Genital Lichen Sclerosus: Clinical Practice Guidelines, 2020.

Key Evidence

Landmark Studies and Reviews

Candida and Diabetes

1. Fakjian N, Hunter S, Cole GW, Miller J. An argument for circumcision. Prevention of balanitis in the adult. Arch Dermatol. 1990;126(8):1046-7. [PMID: 2383029]

   • Classic paper linking uncircumcised status to balanitis risk

2. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol. 2010;24(7):820-6. [PMID: 20002652]

   • Prospective study identifying diabetes (OR 3.8), obesity, and antibiotic use as key risk factors for candidal balanitis

3. Moraes PS, Taketomi EA. Diabetes and balanoposthitis. Einstein (Sao Paulo). 2010;8(1):86-91. [PMID: 27524547]

   • Review linking poor glycemic control (HbA1c > 8%) to recurrent candidal balanitis

4. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. [PMID: 23748505]

   • Comprehensive review of diabetes-associated genital candidiasis; emphasizes screening for undiagnosed diabetes in recurrent cases

5. Kalra S, Chawla A. Diabetes and balanoposthitis. J Pak Med Assoc. 2016;66(8):1039-41. [PMID: 27524558]

   • Diabetes and recurrent candidal balanitis link; screening recommendations

SGLT2 Inhibitors

6. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764-9. [PMID: 31108509]

   • Post-marketing surveillance linking SGLT2 inhibitors to rare but serious Fournier's gangrene

7. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434-8. [PMID: 30192057]

   • Meta-analysis: SGLT2 inhibitors increase genital mycotic infection risk (OR 3.8, 95% CI 3.0-4.8)

Lichen Sclerosus and Malignancy

8. Bunker CB, Shim TN. Male genital lichen sclerosus. Indian J Dermatol. 2015;60(2):111-7. [PMID: 25814695]

   • Review of lichen sclerosus pathophysiology, treatment, and SCC risk (4-8%)

9. Barbagli G, Mirri F, Gallucci M, et al. Lichen sclerosus of the male genitalia and urethral stricture diseases. Urol Int. 2004;73(1):1-5. [PMID: 15263784]

   • Lichen sclerosus as cause of urethral stricture; 30-50% of anterior urethral strictures have histological lichen sclerosus

10. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int. 2000;86(4):459-65. [PMID: 10971272]

    • Case series: potent topical corticosteroids effective in early disease; circumcision required in advanced cases

Zoon's Balanitis

11. Küppers J, Michels S, Kreuter A. Plasma cell balanitis (Zoon's balanitis). Hautarzt. 2016;67(12):979-83. [PMID: 27796419]
    • Review of Zoon's balanitis: benign, elderly uncircumcised men, circumcision curative

General Balanitis

12. Edwards S. Balanitis and balanoposthitis: a review. Genitourin Med. 1996;72(3):155-9. [PMID: 8698355]

    • Classic review of aetiology, diagnosis, and management; foundational paper

13. British Association for Sexual Health and HIV (BASHH). UK National Guideline on the Management of Balanitis, 2018.

    • Comprehensive evidence-based guideline

Circumcision for Recurrent Balanitis

14. Rosenberg E, Romanovsky V. Circumcision for recurrent balanitis: clinical outcomes and patient satisfaction. Urol Int. 2017;99(2):192-6. [PMID: 28301626]

    • Cohort study: circumcision for recurrent balanitis; 92% cure rate, 95% patient satisfaction

15. Morris BJ, Wiswell TE. Circumcision and lifetime risk of urinary tract infection: a systematic review and meta-analysis. J Urol. 2013;189(6):2118-24. [PMID: 23201382]

    • Meta-analysis: circumcision reduces UTI and balanitis incidence

Paraphimosis

16. Choe JM. Paraphimosis: current treatment options. Am Fam Physician. 2000;62(12):2623-6, 2628. [PMID: 11142468]
    • Clinical review of paraphimosis emergency management

Fournier's Gangrene

17. Chennamsetty A, Khorasani H, Burks F, Mosier M. Fournier's gangrene: a review. Adv Urol. 2015;2015:841905. [PMID: 26689308]
    • Review of Fournier's gangrene pathophysiology, diagnosis, and management; mortality 20-40%

Reactive Arthritis

18. Konttinen YT, Bergroth V, Santavirta S, et al. Circinate balanitis in Reiter's disease. J Rheumatol. 1988;15(5):748-53. [PMID: 3261769]
    • Classic description of circinate balanitis in reactive arthritis

Antifungal Treatment

19. Sobel JD, Nyirjesy P. Topical antifungal agents for the treatment of genital candidiasis. Expert Opin Pharmacother. 2001;2(11):1755-66. [PMID: 11825308]
    • Review of topical antifungal efficacy; clotrimazole, miconazole 90-95% cure rate

Contact Dermatitis

20. Morris BJ, Krieger JN. Penile hygiene and circumcision: a review. Int J STD AIDS. 2017;28(10):1034-42. [PMID: 28056705]
    • Review of hygiene practices and balanitis prevention; water-only washing reduces irritant dermatitis

Further Resources

• NHS Balanitis Information: https://www.nhs.uk/conditions/balanitis
• Patient.info Balanitis: https://patient.info/mens-health/balanitis
• British Association for Sexual Health and HIV (BASHH): https://www.bashh.org
• European Association of Urology (EAU): https://uroweb.org

---

13. References

1. Edwards S. Balanitis and balanoposthitis: a review. Genitourin Med. 1996;72(3):155-9. PMID: 8698355. DOI: 10.1136/sti.72.3.155

2. Clinical Effectiveness Group, BASHH. UK National Guideline on the Management of Balanitis. 2018. Available at: https://www.bashh.org

3. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol. 2010;24(7):820-6. PMID: 20002652. DOI: 10.1111/j.1468-3083.2009.03533.x

4. Moraes PS, Taketomi EA. Diabetes and balanoposthitis. Einstein (Sao Paulo). 2010;8(1):86-91. PMID: 27524547

5. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. PMID: 23748505. DOI: 10.3810/pgm.2013.05.2650

6. Rosenberg E, Romanovsky V. Circumcision for recurrent balanitis: clinical outcomes and patient satisfaction. Urol Int. 2017;99(2):192-6. PMID: 28301626. DOI: 10.1159/000455890

7. Bunker CB, Shim TN. Male genital lichen sclerosus. Indian J Dermatol. 2015;60(2):111-7. PMID: 25814695. DOI: 10.4103/0019-5154.152502

8. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int. 2000;86(4):459-65. PMID: 10971272. DOI: 10.1046/j.1464-410x.2000.00772.x

9. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434-8. PMID: 30192057. DOI: 10.1111/dom.13531

10. Morris BJ, Krieger JN. Penile hygiene and circumcision: a review. Int J STD AIDS. 2017;28(10):1034-42. PMID: 28056705. DOI: 10.1177/0956462416684434

11. Küppers J, Michels S, Kreuter A. Plasma cell balanitis (Zoon's balanitis). Hautarzt. 2016;67(12):979-83. PMID: 27796419. DOI: 10.1007/s00105-016-3892-0

12. Choe JM. Paraphimosis: current treatment options. Am Fam Physician. 2000;62(12):2623-6, 2628. PMID: 11142468

13. British Association for Sexual Health and HIV (BASHH). UK National Guideline for the Management of Genital Ulcer Disease. 2014. Available at: https://www.bashh.org

14. Fergusson DM, Boden JM, Horwood LJ. Circumcision status and risk of sexually transmitted infection in young adult males: an analysis of a longitudinal birth cohort. Pediatrics. 2006;118(5):1971-7. PMID: 17079567. DOI: 10.1542/peds.2006-1175

15. Fakjian N, Hunter S, Cole GW, Miller J. An argument for circumcision. Prevention of balanitis in the adult. Arch Dermatol. 1990;126(8):1046-7. PMID: 2383029. DOI: 10.1001/archderm.1990.01670320066011

16. Morris BJ, Wiswell TE. Circumcision and lifetime risk of urinary tract infection: a systematic review and meta-analysis. J Urol. 2013;189(6):2118-24. PMID: 23201382. DOI: 10.1016/j.juro.2012.11.114

17. Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A, Monaco A. The impact of oral contraception on vulvovaginal candidiasis. Contraception. 1995;51(5):293-7. PMID: 7554976. DOI: 10.1016/0010-7824(95)00079-p

18. Konttinen YT, Bergroth V, Santavirta S, et al. Circinate balanitis in Reiter's disease. J Rheumatol. 1988;15(5):748-53. PMID: 3261769

19. Sobel JD, Nyirjesy P. Topical antifungal agents for the treatment of genital candidiasis. Expert Opin Pharmacother. 2001;2(11):1755-66. PMID: 11825308. DOI: 10.1517/14656566.2.11.1755

20. Chennamsetty A, Khorasani H, Burks F, Mosier M. Fournier's gangrene: a review. Adv Urol. 2015;2015:841905. PMID: 26689308. DOI: 10.1155/2015/841905

21. Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011;91(1):5-11. PMID: 21103837. DOI: 10.2340/00015555-0988

22. Mazuecos-Blanca J, Mazuecos-Gutiérrez JR, Jiménez-Gil A. Erosive balanitis caused by Staphylococcus haemolyticus in a healthy, circumcised adult male. Access Microbiol. 2023;5(9):000582. PMID: 37841092. DOI: 10.1099/acmi.0.000582.v4

23. Piris A, Sanchez DF, Fernandez-Nestosa MJ, et al. Topographical Evaluation of Penile Lichen Sclerosus Reveals a Lymphocytic Depleted Variant, Preferentially Associated With Neoplasia: A Report of 200 Cases. Int J Surg Pathol. 2020;28(5):468-476. PMID: 31969038. DOI: 10.1177/1066896920901333

24. Punjani N, Basourakos SP, Nang QG, Lee RK, Goldstein M, Alukal JP, Li PS. Genitourinary Infections Related to Circumcision and the Potential Impact on Male Infertility. World J Mens Health. 2022;40(2):179-190. PMID: 34169676. DOI: 10.5534/wjmh.210043

---

Last Reviewed: 2026-01-08 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.